<DOC>
	<DOCNO>NCT02070107</DOCNO>
	<brief_summary>No 56 % subject Robley Rex Louisville Veterans Administration Medical Center ( VAMC ) prescribe boceprevir-based triple therapy , complete Hepatitis C ( HCV ) treatment prescribe . Of patient complete therapy , primary reason discontinuation side effect ( 48 % ) non-adherence ( 32 % ) . An intervention need improve treatment completion rate subject achieve high SVR rate note SPRINT-2 RESPOND-2</brief_summary>
	<brief_title>Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection</brief_title>
	<detailed_description>This protocol Phase II Open Label Clinical Trial technology-based application `` On-Plan '' ( OP ) expect improve adherence boceprevir-based triple therapy subject chronic genotype 1 hepatitis C infection compare historical control University Louisville . OP use combination smart phone computer-based social support correct non-adherence manage side effect well contingency management ( positive reinforcement ) patient-reported compliance document pill count and/or electronic compliance monitor . 52 consent subject prescribe boceprevir-based triple therapy chronic genotype 1 HCV accord U.S. prescribing information enrol receive OP application . A Simon 's two stage procedure utilized minimize risk preliminary efficacy/safety data collect innovative `` app '' HCV therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>The subject must meet ALL criterion list entry : 1 . Each subject must willing able provide write informed consent trial . 2 . Subjects must willing adhere dose visit schedule . 3 . Each subject must &gt; 18years age . 4 . Each subject 's weight must ≥ 40 kg ≤ 125 kg . 5 . Subject must previously document HCV genotype 1 infection . Subjects mixed genotype eligible . The HCVRNA result obtain central laboratory Screening Visit must confirm HCV genotype 1 infection HCV RNA &gt; 10,000 IU/mL . Patients may either treatment naïve previously treat long treated protease inhibitor . Patients may compensate cirrhosis . 6 . Subject subject 's partner ( ) must agree use acceptable method contraception least 2 week prior Day 1 continue least 6 month last dose study medication , longer dictate local regulation . Postmenopausal woman require use contraception . Postmenopausal define least 12 consecutive month without spontaneous menstrual period . Each sexually active male subject female partner ( ) childbearing potential must also provide write informed consent provide information regard pregnancy . The subject exclude entry ANY criterion list meet : 1 . Subject age legal consent , mentally legally incapacitate , significant emotional problem time prestudy screen visit expect conduct study history clinically significant psychiatric disorder , opinion investigator , would interfere study procedure . 2 . Subjects coinfected human immunodeficiency virus ( HIV ) hepatitis B virus ( Hepatitis B surface antigen [ HBsAg ] HIV positive . 3 . Treatment hepatitis C investigational medication . Prior treatment herbal remedy know hepatotoxicity exclusionary . All herbal remedy include limited St. John 's Wort ( Hypericum perforatum ) use hepatitis C treatment must discontinue Day 1 . Only silibinin base product silymarin ( milk thistle ) allow trial . 4 . Subjects receive follow medication ( ) within 2 week prior Day 1 visit highly dependent CYP3A4/5 clearance , elevate plasma concentration could associate serious and/or lifethreatening event orally administer midazolam , pimozide , amiodarone , flecainide , propafenone , quinidine , ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) . The following medication also exclusionary take within 2 week prior Day 1 visit : alfuzosin , cisapride , triazolam , sildenafil , tadalafil ( latter 2 use indication chronic obstructive pulmonary disease ( COPD ) . 5 . Participation clinical trial within 30 day screen visit trial intention participate another clinical trial participation trial . Collection additional blood , urine , tissue sample additional data , beyond specify protocol , prohibit ( related subject 's medical care ) . 6 . Evidence decompensated liver disease . 7 . Subject evidence hepatocellular carcinoma ( HCC ) evaluation HCC . 8 . Subject diabetic and/or hypertensive clinically significant ocular examination finding within 6 month prior screen visit screen visit Day 1 : retinopathy , cotton wool spot , optic nerve disorder , retinal hemorrhage , clinically significant abnormality . 9 . Subject preexist psychiatric condition ( ) include limit : Current moderate severe depression history severe psychiatric disturbance . 10 . Subject clinical diagnosis substance abuse investigator follow specified drug within specify timeframes : 1 . Alcohol , intravenous drug , inhalational ( include marijuana ) , psychotropics , narcotic , cocaine use , prescription overthecounter drug : within 1 year screen visit , OR 2 . Multidrug abuse ( e.g. , two substance list Exclusion Criterion 10a within 3 year screen visit , OR 3 . Subjects receive opiate agonist substitution therapy within 1 year screen visit ( except subject monitor opioid substitution maintenance program specify Section 7.3.5 ) OR 4 . Subject 's historic marijuana use deem excessive physician investigator interfere subject 's daily function . If subject 's marijuana use deem excessive interfere daily function , subject must instruct discontinue current use recreational marijuana prior entry trial throughout trial period . 11 . Subject know medical condition could interfere subject 's participation completion trial , include , limited : 1 . Central nervous system ( CNS ) trauma require intubation , intracranial pressure monitoring , brain meningeal skull surgery , result seizure , coma , permanent neurologic deficit , abnormal brain imaging , cerebral spinal fluid ( CSF ) leak . Prior brain hemorrhage and/or intracranial aneurysm ( whether adequately repair ) . 2 . Current uncontrolled seizure disorder unless control stable medical regimen interact boceprevir . 3 . History stroke transient ischemic attack . 4 . Immunologically mediated disease ( e.g. , inflammatory bowel disease [ Crohn 's disease , ulcerative colitis ] , celiac disease , rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , sarcoidosis , severe psoriasis require oral inject treatment , symptomatic thyroid disorder ) . 5 . Clinically significant chronic pulmonary disease ( e.g. , clinical chronic obstructive pulmonary disease , interstitial lung disease , pulmonary fibrosis , sarcoidosis ) . 6 . Current history clinically significant cardiac abnormalities/dysfunction ( e.g. , angina , congestive heart failure , myocardial infarction , pulmonary hypertension , complex congenital heart disease , cardiomyopathy , significant arrhythmia ) include current uncontrolled hypertension , history use antianginal agent cardiac condition , clinically significant abnormality ECG perform prestudy screen visit . 7 . Any medical condition requiring , likely require , chronic systemic administration corticosteroid course trial . 8 . Clinically significant gout within last year . 9 . Clinically significant hemoglobinopathy , include , limited , thalassemia major . 10 . Myelodysplastic syndrome . 11 . Coagulopathy , include , limited , hemophilia . 12 . Organ transplant ( include hematopoietic stem cell transplant ) cornea hair . 13 . Poor venous access precludes routine peripheral blood sampling require trial . 14 . Subject history gastric surgery ( e.g. , staple , bypass ) subject history malabsorption disorder ( e.g. , celiac sprue disease ) . p ) Other serious medical condition could exacerbate pegIFN alfa2a and/or RBV , opinion investigator . 12 . Subject evidence active suspected malignancy , history malignancy , within last 5 year ( except adequately treat carcinoma situ basal cell carcinoma skin . Subjects evaluation malignancy eligible . 13 . Female subject pregnant , lactating , expect conceive donate egg OR Male subject plan impregnate provide sperm donation female sexual partner pregnant childbearing potential unwilling commit use two method birth control throughout treatment completion treatment ( see Inclusion Criterion ) . 14 . Subject condition , opinion principal investigator physician , would make subject unsuitable enrollment could interfere subject participate completing study . 15 . Subject lifethreatening SAE screen period . 16 . Subject member family member investigational study staff sponsor staff directly involve study . Laboratory Exclusion Criteria Note : If laboratory exclusion criterion meet , site may subject retested . If single value within 10 % listed laboratory exclusion criterion value , value consider clinically significant investigator , subject may consider enrollment . The value platelets count retested . 1 . Hemoglobin &lt; 10 g/dL female &lt; 11 g/dL male . 2 . Neutrophils &lt; 1500/mm3 , &lt; 1,200/mm3 subject African descent . 3 . Platelets &lt; 60,000/mm3 ; may retested variance allow entry criterion . 4 . Thyroid disorder : 1 . The subject may enrol clinically euthyroid , AND 2 . The euthyroid function confirm thyroxine/triiodothyronine ( T4/T3 ) test . 5 . Serum glucose : Hemoglobin A1C &gt; 8.5 % . 6 . Positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>